会议召开地点：上海证券交易所上证路演中心（网址：http://roadsho w.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2023 年 5 月 4 日(星期四) 至 5 月 10 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过西藏卫信康医药股份有 限公司（以下简称"公司"）邮箱 wxk@wxkpharma.com 进行提问。公司将在信息 披露允许的范围内，在说明会上对投资者普遍关注的问题进行回答。 公司已于 2023 年 4 月 26 日发布公司 2022 年年度报告、2023 年第一季度报 告，为便于广大投资者更全面深入地了解公司 2022 年度、2023 年第一季度经营 成果、财务状况，公司计划于 2023 年 5 月 11 日 15:00-16:00 举行 2022 年度暨 2023 年第一季度业绩说明会，就投资者关心的问题进行交流。 证券代码：603676 证券简称：卫信康 公告编号：2023-020 西藏卫信康医药股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证 ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-------------------------|---------------------------------------|--------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | | 编号： 2022-011 | | | | | | | | □特定对象调研 | □分析师会议 | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | 类别 | □新闻发布会 | ■路演活动 | | | | □现场参观 | | | | | ■其他：电话会议 | | | | 参与单位名称及 人员 ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------|-----------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------| | | | | 编号： 2022-010 | | | | | | | | □特定对象调研 □分析师会议 | | | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | | 类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | ■其他：电话会议 | ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 编号：2022-012 | --- | --- | --- | --- | --- | |----------------|----------------------------------------------------------|----------------------------------|-------|--------------------| | | | | | | | | □特定对象调研 | □分析师会议 | | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | | 类别 | □新闻发布会 | □路演活动 | | | | | □现场参观 | | | | | | ■其他：电话会议 | | | | | 参与单位名称及 | 东吴证券、太平资管 | | | | | 人员姓名 | 华西证券、农银汇理基金 2022 年 05 月 17 日， | 15:00-16:00 | | | | 时间 | 年 月 日， | | | | | 地点 | 2022 05 18 | 10:00-11:1 ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------|---------------------------------------|------------------------------------------------|---------------------------------------------------------------------------------------------------------------| | | | | 编号： 2022-017 | | | | | | | | □特定对象调研 | □分析师会议 | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | 类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | ■其他：电话会议 | | | | 参与单位名称及 | 华西证券：王帅、王雨珩 | | | | 人员姓名 | 新华基金：赵东宇、李娜 | | | | 时间 | ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------|-----------------------------------------------------|-------------------------------------------------------------------------------------------------------|------------------------------------| | | | | 编号： 2022-016 | | | □特定对象调研 | □分析师会议 | | | | □媒体采访 | □业绩说明会 | | | 投资者关系活动 | □新闻发布会 | □路演活动 | | | 类别 | □现场参观 | | | | | ■其他：电话会议 | | | | 参与单位名称及 | 中泰证券：李霁阳 | | | | 人员姓名 | 国泰基金：申坤、亿林、叶烽、张慧芝 | | | | 时间 | 2022 年 6 月 23 日 | 1 ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |-------------------------|-------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------|------------------------| | | | | 编号： | 2022-018 | | | | | | | | | □特定对象调研 | □分析师会议 | | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | | 类别 | □新闻发布会 | □路演活动 | | | | | □现场参观 | | | | | | ■其他：电话会议 | | | | | 参与单位名称及 人员姓名 | 民生证券：许睿、孙怡 | ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 编号：2022-014 | --- | --- | --- | --- | |----------------|--------------------------------------|------------------------------------------------------|-------| | | | | | | | | | | | | □特定对象调研 | □分析师会议 | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | 类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | ■其他：电话会议 | | | | | 2022 年 06 月 02 日 | | | | | | 东吴证券：秦凯、宋金洋、周新明、黄海珠、朱国广 | | | | 宝盈基金：刘迪、姚艺、朱建明 | | | | | 中信保诚：陈爽、杨强 | | | | | | 华夏基金：胥梦缘、周天翎、孙明达、陈斌 | | | | 建信基金：马牧青、郑丁源 | | | | | 信达澳银：李 ...

2022 年第三季度报告 证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 单位：元 币种：人民币 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告 期比上 | | 年初至报告 | | --- | --- | --- | --- | --- | | | | 年同期 | | 期末比上年 | | 项目 | 本报告期 | 增减变 | 年初至报告期末 | 同期增减变 | | | | 动幅度 | | 动幅度(%) | | | | (%) | | | | 营业收入 | 399,119,537.8 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥668,037,447.12, representing a 33.63% increase compared to ¥499,908,008.39 in the same period last year[20]. - The net profit attributable to shareholders of the listed company reached ¥102,972,074.23, a significant increase of 93.10% from ¥53,325,052.50 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was ¥101,656,588.34, up 95.66% from ¥51,955,608.05 year-on-year[20]. - The net cash flow from operating activities was ¥116,045,617.93, an increase of 84.21% compared to ¥62,996,620.47 in the same period last year[20]. - Basic earnings per share for the reporting period were ¥0.24, an increase of 84.62% compared to ¥0.13 in the same period last year[21]. - The weighted average return on net assets rose to 9.20%, an increase of 3.88 percentage points from 5.32% in the previous year[21]. - The company reported a total non-recurring profit and loss of RMB 1,315,485.89, with government subsidies contributing RMB 1,654,809.92 and non-current asset disposal losses of RMB -20,255.18[24]. - The company reported a net loss of 8,275,500 RMB for the period, indicating a challenging financial environment[124]. Market and Product Development - The company attributed the revenue and profit growth primarily to increased sales of its main products[22]. - The company has not disclosed any new product developments, market expansions, or mergers and acquisitions in this report[19]. - The company focuses on the development of chemical drug formulations and raw materials, with a strong competitive edge in compound vitamins, trace elements, and electrolytes[30]. - The company has established a product matrix including injectable multivitamins, multielement injections, and pediatric multivitamin injections, enhancing its market influence[32]. - The company aims to meet clinical needs through innovative research and development, maintaining a focus on both generic and innovative products[30]. - The company is committed to enhancing its research capabilities to address unmet clinical needs in high market potential areas[31]. - The company has developed a total of 30 new product projects currently under research, with 14 invention patents and 17 new drug certificates obtained since 2015[48]. - The company is actively pursuing new product approvals, with over 30 research and development projects underway, and expects to obtain approval for 2 products in the second half of 2022[56]. Industry Context - In the first half of 2022, the pharmaceutical manufacturing industry achieved revenue of RMB 14,007.8 billion, a year-on-year decrease of 0.6%, and total profit of RMB 2,209.5 billion, down 27.6%[27]. - The average price reduction for selected drugs in the sixth batch of national drug procurement was 53%, significantly impacting the pharmaceutical industry[28]. - The pharmaceutical industry is experiencing structural upgrades driven by ongoing drug procurement reforms and the promotion of innovative drug development[28]. Environmental and Social Responsibility - The company reported a COD discharge of 3.20 tons during the reporting period, within the permitted total of 8.76 tons per year[85]. - The ammonia nitrogen discharge was 0.45 tons, also within the permitted total of 1.31 tons per year[85]. - The company’s subsidiary was listed as a key pollutant discharge unit, focusing on water environment management[83]. - The company is committed to maintaining high-quality development while supporting national pandemic prevention efforts[74]. - The company invested CNY 246,600 in poverty alleviation and rural revitalization efforts in the first half of 2022[98]. - The company actively participated in local government poverty alleviation activities and provided support to specific schools and impoverished families in the Naqu region[98]. Corporate Governance and Shareholder Relations - The company committed to ensuring that shareholders with over 5% holdings will not reduce their shares by more than 10% of their total holdings in any given year after the lock-up period[101]. - The controlling shareholder and actual controller made commitments to avoid any business competition with the company and its subsidiaries[104]. - The company will not provide any financial assistance or loans to incentive recipients under its 2021 restricted stock incentive plan[106]. - The company has implemented a stock incentive plan to optimize its compensation structure and maintain core team stability, contributing to long-term performance stability[51]. Research and Development - The company has implemented differentiated sales strategies for key products, including multi-vitamin injections and electrolyte solutions, to maximize market penetration[61]. - The company is focusing on high-quality generic drug development and has made significant progress in the consistency evaluation of its products[56]. - The company has established three core technology platforms, including new injection technology, complex formulation technology, and new freeze-drying technology[48]. - The company is focusing on enhancing its R&D capabilities and expanding its market presence through strategic initiatives[135]. Financial Position and Assets - The total assets at the end of the reporting period were ¥1,570,306,370.01, reflecting a 5.00% increase from ¥1,495,569,265.97 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company increased by 5.49% to ¥1,125,874,394.24 from ¥1,067,264,112.89 at the end of the previous year[20]. - Total liabilities increased to CNY 444,431,975.77 from CNY 428,305,153.08, reflecting a rise of approximately 3.6%[134]. - The company’s total liabilities were reported at CNY 126,440,000.00, indicating a stable financial position[160]. Operational Efficiency - The company employs a procurement model that includes both production and non-production materials, optimizing inventory and procurement cycles[44]. - The sales model is based on regional terminal distribution, leveraging strong market competitiveness and selecting qualified distributors[47]. - The company has implemented a collaborative production model with partners, ensuring quality control and compliance with regulatory standards[46]. - The company’s production activities are managed under strict GMP standards, ensuring high-quality manufacturing processes[45].